Abstract:There is great interest in drugs that are capable of modulating multiple aging pathways, thereby delaying the onset and progression of aging. Effective strategies for drug development include the repurposing of existing drugs already approved by the FDA for human therapy. FDA approved drugs have known mechanisms of action and have been thoroughly screened for safety. Although there has been extensive scientific activity in repurposing drugs for disease therapy, there has been little testing of these drugs for their effects on aging. The pool of FDA approved drugs therefore represents a large reservoir of drug candidates with substantial potential for anti-aging therapy. In this paper we employ FINDSITEcomb, a powerful ligand homology modeling program, to identify binding partners for proteins produced by temperature sensing genes that have been implicated in aging. This list of drugs with potential to modulate aging rates was then tested experimentally for lifespan and healthspan extension using a small invertebrate model. Three protein targets of the rotifer Brachionus manjavacas corresponding to products of the transient receptor potential gene 7, ribosomal protein S6 polypeptide 2 gene, or forkhead box C gene, were screened against a compound library consisting of DrugBank drugs including 1347 FDA approved, non-nutraceutical molecules. Twenty nine drugs ranked in the top 1 % for binding to each target were subsequently included in our experimental analysis. Continuous exposure of rotifers to 1 µM naproxen significantly extended rotifer mean lifespan by 14 %. We used three endpoints to estimate rotifer health: swimming speed (mobility proxy), reproduction (overall vitality), and mitochondria activity (cellular senescence proxy). The natural decline in swimming speed with aging was more gradual when rotifers were exposed to three drugs, so that on day 6, mean swimming speed of females was 1.19 mm/s for naproxen (P = 0.038), 1.20 for fludarabine (P = 0.040), 1.35 for hydralazine (P = 0.038), as compared to 0.88 mm/s in the control. The average reproduction of control females in the second half of their reproductive lifespan was 1.08 per day. In contrast, females treated with 1 µM naproxen produced 1.4 offspring per day (P = 0.027) and females treated with 10 µM fludarabine or 1 µM hydralazine produced 1.72 (P = <0.001) and 1.66 (P = 0.001) offspring per day, respectively. Mitochondrial activity naturally declines with rotifer aging, but B. manjavacas treated with 1 µM hydralazine or 10 µM fludarabine retained 49 % (P = 0.038) and 89 % (P = 0.002) greater mitochondria activity, respectively, than untreated controls. Our results demonstrate that coupling computation to experimentation can quickly identify new drug candidates with anti-aging potential. Screening drugs for anti-aging effects using a rotifer bioassay is a powerful first step in identifying compounds worthy of follow-up in vertebrate models. Even if lifespan extension is not observed, certain drugs could improve healthspan, slowing age-dependent losses in mobility and vitality.

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization

A Pragmatic Approach to Introducing Translational Geroscience Into the Clinic: A Paradigm Based on the Incremental Progression of Aging-Related Clinical Research

Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic

Methods for the discovery of new anti-aging products – targeted approaches

Geroscience and pathology: a new frontier in understanding age-related diseases

Geroscience: Addressing the mismatch between its exciting research opportunities, its economic imperative and its current funding crisis

Aging, Senescent Cells, and Senolytic Drugs: The Path to Translation

Human aging and disease: Lessons from age-related macular degeneration

Targeting Senescent Cells for a Healthier Longevity: the Roadmap for an Era of Global Aging

Repurposing metformin: an old drug with new tricks in its binding pockets

A new clinical age of aging research

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease

Addressing the gaps in evaluation of new drugs for older adults: Strategies from the International Union of Basic and Clinical Pharmacology (IUPHAR) Geriatric Committee

Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies

Therapeutics That Can Potentially Replicate or Augment the Anti-Aging Effects of Physical Exercise

Repurposing FDA-approved drugs for anti-aging therapies

Advancing Longevity: Exploring Antiaging Pharmaceuticals in Contemporary Clinical Trials Amid Aging Dynamics

Drug discovery for ageing: SIMPs, NEDs and screening challenges

Targeting the Mitochondria-Proteostasis Axis to Delay Aging